|
1
|
Massague J, Blain SW and Lo RS: TGFbeta
signaling in growth control, cancer, and heritable disorders. Cell.
103:295–309. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hughes C, Bauer E and Roberts AP: Spread
of R-plasmids among Escherichia coli causing urinary tract
infections. Antimicrob Agents Chemother. 20:496–502. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruna A, Darken RS, Rojo F, et al: High
TGFbeta-Smad activity confers poor prognosis in glioma patients and
promotes cell proliferation depending on the methylation of the
PDGF-B gene. Cancer Cell. 11:147–160. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Penuelas S, Anido J, Prieto-Sanchez RM, et
al: TGF-beta increases glioma-initiating cell self-renewal through
the induction of LIF in human glioblastoma. Cancer Cell.
15:315–327. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sawyer JS, Beight DW, Britt KS, et al:
Synthesis and activity of new aryl- and heteroaryl-substituted
5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the
transforming growth factor-beta type I receptor kinase domain.
Bioorg Med Chem Lett. 14:3581–3584. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anido J, Saez-Borderias A, Gonzalez-Junca
A, et al: TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high)
Glioma-Initiating Cell Population in Human Glioblastoma. Cancer
Cell. 18:655–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li HY, Wang Y, Yan L, et al: Novel and
potent transforming growth factor beta type I receptor kinase
domain inhibitor: 7-amino
4-(2-pyridin-2-yl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-quinolines.
Bioorg Med Chem Lett. 14:3585–3588. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Anderton MJ, Mellor HR, Bell A, et al:
Induction of heart valve lesions by small-molecule ALK5 inhibitors.
Toxicol Pathol. 39:916–924. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bueno L, de Alwis DP, Pitou C, et al:
Semi-mechanistic modelling of the tumour growth inhibitory effects
of LY2157299, a new type I receptor TGF-beta kinase antagonist, in
mice. Eur J Cancer. 44:142–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gueorguieva I, Cleverly AL, Stauber A, et
al: Defining a therapeutic window for the novel TGF-ᵝ inhibitor
LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic
model. Br J Clin Pharmacol. 77:796–807. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vredenburgh JJ, Desjardins A, Herndon JE
II, et al: Phase II trial of bevacizumab and irinotecan in
recurrent malignant glioma. Clin Cancer Res. 13:1253–1259. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lenato GM and Guanti G: Hereditary
Haemorrhagic Telangiectasia (HHT): Genetic and molecular aspects.
Curr Pharm Des. 12:1173–1193. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lechleider RJ, Ryan JL, Garrett L, et al:
Targeted mutagenesis of Smad1 reveals an essential role in
chorioallantoic fusion. Dev Biol. 240:157–167. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li F, Lan Y, Wang Y, et al: Endothelial
Smad4 maintains cerebrovascular integrity by activating N-cadherin
through cooperation with Notch. Dev Cell. 20:291–302. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dickinson ME, Selleck MA, McMahon AP and
Bronner-Fraser M: Dorsalization of the neural tube by the
non-neural ectoderm. Development. 121:2099–2106. 1995.PubMed/NCBI
|
|
16
|
Oshima M, Oshima H and Taketo MM: TGF-beta
receptor type II deficiency results in defects of yolk sac
hematopoiesis and vasculogenesis. Dev Biol. 179:297–302. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goumans MJ, Valdimarsdottir G, Itoh S, et
al: Balancing the activation state of the endothelium via two
distinct TGF-beta type I receptors. EMBO J. 21:1743–1753. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gerstner ER, Sorensen AG, Jain RK and
Batchelor TT: Advances in neuroimaging techniques for the
evaluation of tumor growth, vascular permeability, and angiogenesis
in gliomas. Curr Opin Neurol. 21:728–735. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pechman KR, Donohoe DL, Bedekar DP, et al:
Evaluation of combined bevacizumab plus irinotecan therapy in brain
tumors using magnetic resonance imaging measures of relative
cerebral blood volume. Magn Reson Med. 68:1266–1272. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sorensen AG, Emblem KE, Polaskova P, et
al: Increased survival of glioblastoma patients who respond to
antiangiogenic therapy with elevated blood perfusion. Cancer Res.
72:402–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hilario A, Ramos A, Perez-Nunez A, et al:
The added value of apparent diffusion coefficient to cerebral blood
volume in the preoperative grading of diffuse gliomas. AJNR Am J
Neuroradiol. 33:701–707. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Maeda M, Itoh S, Kimura H, et al: Tumor
vascularity in the brain: Evaluation with dynamic
susceptibility-contrast MR imaging. Radiology. 189:233–238. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Aronen HJ, Gazit IE, Louis DN, et al:
Cerebral blood volume maps of gliomas: Comparison with tumor grade
and histologic findings. Radiology. 191:41–51. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Donahue KM, Krouwer HG, Rand SD, et al:
Utility of simultaneously acquired gradient-echo and spin-echo
cerebral blood volume and morphology maps in brain tumor patients.
Magn Reson Med. 43:845–853. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Law M, Oh S, Babb JS, et al: Low-grade
gliomas: Dynamic susceptibility-weighted contrast-enhanced
perfusion MR imaging - prediction of patient clinical response.
Radiology. 238:658–667. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sugahara T, Korogi Y, Tomiguchi S, et al:
Posttherapeutic intraaxial brain tumor: The value of
perfusion-sensitive contrast-enhanced MR imaging for
differentiating tumor recurrence from nonneoplastic
contrast-enhancing tissue. AJNR Am J Neuroradiol. 21:901–909.
2000.PubMed/NCBI
|
|
27
|
Rodon Ahnert J, Baselga J, Calvo E, et al:
First human dose (FHD) study of the oral transforming growth
factor-beta receptor I kinase inhibitor LY2157299 in patients with
treatment-bractory malignant glioma. J Clin Oncol. 29:abstract
3011. 2011.
|
|
28
|
Azaro A, Baselga J, Sepulveda JM, et al:
The oral transforming growth factor-beta (TGF-β) receptor I kinase
inhibitor LY2157299 plus lomustine in patients with
treatment-bractory malignant glioma: The first human dose study. J
Clin Oncol. 30:abstract 2042. 2012.
|
|
29
|
Trotti A, Colevas AD, Setser A, et al:
CTCAE v3.0: development of a comprenhensive grading system for the
adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oken MM, Creech RH, Tormey DC, et al:
Toxicity and response criteria of the Eastern Cooperative Oncology
Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Macdonald DR, Cascino TL, Schold SC Jr and
Cairncross JG: Response criteria for phase II studies of
supratentorial malignant glioma. J Clin Oncol. 8:1277–1280.
1990.PubMed/NCBI
|
|
32
|
Vidiri A, Pace A, Fabi A, et al: Early
perfusion changes in patients with recurrent high-grade brain tumor
treated with Bevacizumab: Preliminary results by a quantitative
evaluation. J Exp Clin Cancer Res. 31:332012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Thompson G, Mills SJ, Coope DJ, et al:
Imaging biomarkers of angiogenesis and the microvascular
environment in cerebral tumours. Br J Radiol. 84:S127–S144. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jenkinson MD, Smith TS, Joyce KA, et al:
Cerebral blood volume, genotype and chemosensitivity in
oligodendroglial tumours. Neuroradiology. 48:703–713. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kappelle AC, Postma TJ, Taphoorn MJ, et
al: PCV chemotherapy for recurrent glioblastoma multiforme.
Neurology. 56:118–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wick W, Puduvalli VK, Chamberlain MC, et
al: Phase III study of enzastaurin compared with lomustine in the
treatment of recurrent intracranial glioblastoma. J Clin Oncol.
28:1168–1174. 2010. View Article : Google Scholar : PubMed/NCBI
|
